tert-butyl (3R*,4S*)-3-(4-fluorophenyl)-4-hydroxypiperidine-1-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl (3R*,4S*)-3-(4-fluorophenyl)-4-hydroxypiperidine-1-carboxylate
• 英文别名: 1-tert-butoxycarbonyl-3-(4-fluoro-phenyl)-4-hydroxypiperidine；Tert-butyl 3-(4-fluorophenyl)-4-hydroxypiperidine-1-carboxylate
• 化学式: C₁₆H₂₂FNO₃
• 分子量: 295.354
• InChiKey: GTJAOYZAMZKAOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  三氯乙腈 、 tert-butyl (3R*,4S*)-3-(4-fluorophenyl)-4-hydroxypiperidine-1-carboxylate 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 乙醚 为溶剂， 反应 2.42h， 生成 (1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl 2,2,2-trichloroethanimidate
  参考文献：
  名称：

  WO2006/57921

  摘要：

  公开号：
• 作为产物：
  描述：

  tert-butyl 3-(4-fluorophenyl)-4-oxopiperidine-1-carboxylate 在 lithium aluminium tetrahydride 、 sodium hydroxide 、 水 作用下， 以 四氢呋喃 、 diethyl eter 、 乙醚 为溶剂， 反应 7.0h， 生成 tert-butyl (3R*,4S*)-3-(4-fluorophenyl)-4-hydroxypiperidine-1-carboxylate
  参考文献：
  名称：

  WO2006/57977

  摘要：

  公开号：

文献信息

• NK1 and NK3 antagonists
  申请人：O'Neill T. Brian

  公开号：US20050256164A1

  公开（公告）日：2005-11-17

  The invention is to a compound exhibiting neurokinin inhibitory properties, a pharmaceutical composition comprising same and a method of treatment for neurokinin-mediated conditions.

  这项发明涉及一种具有神经激肽抑制性能的化合物，包括该化合物的药物组合物以及用于神经激肽介导疾病的治疗方法。
• Piperidine derivative, process for producing the same, and use
  申请人：Ikeura Yoshinori

  公开号：US20060167052A1

  公开（公告）日：2006-07-27

  The present invention provides a compound represented by the formula: wherein Ar is an aryl group, an aralkyl group or an aromatic heterocyclic group, each of which may be substituted, R 1 is a hydrogen atom, an optionally substituted hydrocarbon group, an acyl group or an optionally substituted heterocyclic group, X is an oxygen atom or an optionally lo substituted imino group, Z is an optionally substituted methylene group, Ring A is an optionally further substituted piperidine ring, and Ring B is an optionally substituted aromatic ring, provided that when Z is a methylene group substituted with an oxo group, R 1 is not a methyl group, and 15 when Z is a methylene group substituted with a methyl group, Ring B is a substituted aromatic ring, or a salt thereof, which is a novel piperidine derivative having excellent antagonistic action for a tachykinin receptor and useful as a medicament, particularly an agent for preventing and/or treating urinary frequency and/or urinary incontinence.

  本发明提供了一种化合物，其表示为以下式子：其中Ar是芳基、芳基烷基或芳香杂环基，每个基团都可以被取代，R1是氢原子、可选取代的碳氢基团、酰基或可选取代的杂环基团，X是氧原子或可选取代的亚胺基团，Z是可选取代的亚甲基团，环A是可选进一步取代的哌啶环，环B是可选取代的芳香环，但当Z是取代有氧基的亚甲基团时，R1不是甲基基团，而当Z是取代有甲基基团的亚甲基团时，环B是取代的芳香环，或其盐。该化合物是一种新型哌啶衍生物，具有优异的缓解速激肽受体拮抗作用，可用作药物，特别是用作预防和/或治疗尿频和/或尿失禁的药剂。
• Cycloalkyl Keto Piperidine Tachykinin Receptor Antagonists
  申请人：DeVita J. Robert

  公开号：US20080076783A1

  公开（公告）日：2008-03-27

  The present invention is directed to certain piperidine compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

  本发明涉及某些哌啶化合物，其作为神经激肽-1（NK-1）受体拮抗剂和快速激肽，特别是物质P的抑制剂是有用的。本发明还涉及包含这些化合物作为活性成分的制药配方，并且涉及将这些化合物及其配方用于治疗某些疾病，包括呕吐、尿失禁、抑郁症和焦虑症。
• Piperidinyl Piperidine Tachykinin Receptor Antagonists
  申请人：Devita Robert J.

  公开号：US20080146588A1

  公开（公告）日：2008-06-19

  The present invention is directed to certain piperidine compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

  本发明涉及某些哌啶化合物，其可用作神经激肽1（NK-1）受体拮抗剂，并且是缓激肽，特别是物质P的抑制剂。本发明还涉及包含这些化合物作为活性成分的制药配方以及利用这些化合物及其配方治疗某些疾病，包括呕吐、尿失禁、抑郁症和焦虑症。
• Cycloalkyl Piperidine Tachykinin Receptor Antagonists
  申请人：DeVita Robert J.

  公开号：US20080153851A1

  公开（公告）日：2008-06-26

  The present invention is directed to certain piperidine compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

  本发明涉及某些哌啶类化合物，其可用作神经激肽-1（NK-1）受体拮抗剂，以及缓激肽和特别是物质P的抑制剂。本发明还涉及包含这些化合物作为活性成分的药物配方，以及这些化合物及其配方在治疗某些疾病，包括呕吐、尿失禁、抑郁症和焦虑症方面的使用。